DaVita Beats Q4 Estimates on Strong Clinical Execution, Eyes Growth Amid Cost Headwinds
DaVita Inc. (NYSE: DVA) reported fourth-quarter revenue and profit that topped Wall Street forecasts, driven by higher revenue per treatment and its integrated care programs. While margins faced pressure, the company outlined a 2026 roadmap focused on clinical initiatives and partnerships to spur patient growth.